Kathleen Moore, MD, discusses the unmet clinical needs in platinum-resistant ovarian cancer.
Kathleen Moore, MD, director of the Oklahoma TSET Phase I Clinical Trials Program, and associate professor in the Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director of the Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the unmet clinical needs in platinum-resistant ovarian cancer.
Women who recur following frontline therapy have a high unlikelihood of cure, explains Moore. Patients who develop platinum-resistant disease will typically receive chemotherapy plus bevacizumab (Avastin), based on the AURELIA study.
Following that regimen, there are limited treatment options for patients, explains Moore. Moreover, these options are not associated with high rates of response.
Clinical trials may offer eligible patients an alternative treatment option, says Moore.
Developing effective biomarker-driven agents that can produce durable responses while maintaining good quality of life is critical for this patient population and would fill a current unmet clinical need, concludes Moore.